Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.50 |
| ▸ | LAP3 | P28838 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.43 |
| ▸ | GRN | P28799 | 1/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7150981 | 1.00 | MAPT (0.53) | MAPTOPRD1ALDH1A1OPRM1OPRK1 | |
| SCHEMBL30661448 | 0.97 | OPRD1 (0.53) | MAPTOPRD1ALDH1A1OPRM1OPRK1 | |
| SCHEMBL30661446 | 0.97 | OPRD1 (0.53) | MAPTOPRD1ALDH1A1OPRM1OPRK1 | |
| SCHEMBL29414403 | 0.93 | MAPT (0.49) | MAPTOPRD1ALDH1A1OPRM1OPRK1 | |
| SCHEMBL29630425 | 0.91 | OPRD1 (0.55) | MAPTOPRD1ALDH1A1OPRM1OPRK1 | |
| SCHEMBL30285977 | 0.91 | OPRD1 (0.49) | MAPTOPRD1ALDH1A1OPRM1OPRK1 | |
| SCHEMBL29700057 | 0.91 | MME (0.54) | MAPTOPRD1ALDH1A1OPRM1OPRK1 | |
| SCHEMBL29815598 | 0.90 | PTGS1 (0.49) | MAPTOPRD1ALDH1A1OPRM1OPRK1 | |
| SCHEMBL29544382 | 0.90 | MME (0.44) | MAPTOPRD1ALDH1A1OPRM1OPRK1 | |
| SCHEMBL29590916 | 0.89 | ALDH1A1 (0.51) | MAPTOPRD1ALDH1A1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020173452-A1 | Cytostatic-glycoconjugates having specifically cleavable linking units | BAYER AKTIENGESELLSCHAFT (DE) | 2002-11-21 | — | — | US | disclosed |
| WO-2002051862-A2 | CYTOSTATIC-GLYCOCONJUGATES HAVING SPECIFICALLY CLEAVABLE PEPTIDICLINKING UNITS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-07-04 | — | — | WO | disclosed |
| EP-1219634-A1 | Cytostatic-glycoconjugates having specifically cleavable peptidic linking units | Bayer Aktiengesellschaft (DE) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173452-A1 | Cytostatic-glycoconjugates having specifically cleavable linking units | CTSE, CTSL, CTSZ | MAPT 1444/4885OPRD1 4478/4885ALDH1A1 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.